circ_SIRT1上调ATG12,通过与EIF4A3相互作用,促进CML中Imatinib的耐药性
Rong Zhang1, Jinjin Hao1, Hui Yu1
1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Gene
|October 22, 2023
概括
一种新的循环RNA,circ_SIRT1,在耐伊马替尼布的慢性髓性白血病 (CML) 中被上调. 抑制circ_SIRT1可以通过向自和EIF4A3来克服耐药性,为CML患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 伊马替尼是慢性髓性白血病 (CML) 的标准治疗方法.
- 对伊马替尼布的耐药性限制了CML治疗的有效性.
- 循环RNAs (circRNAs) 在癌症进展和耐药性方面发挥作用.
研究的目的:
- 为了确定新型的治疗点对Imatinib耐药的CML.
- 研究circ_SIRT1在CML耐药性的作用.
主要方法:
- 在CML中发现circ_SIRT1表达式.
- 在K562/R细胞中击倒了circ_SIRT1.
- 评估了细胞活力,入侵,细胞亡和自.
- 研究了circ_SIRT1,EIF4A3和ATG12之间的相互作用.
主要成果:
- circ_SIRT1在CML上调并与药物耐药性相关.
- 在K562/R细胞中,circ_SIRT1 knockdown降低了细胞活力,入侵,并增强了细胞亡.
- circ_SIRT1抑制减弱了自和降低了对伊马替尼布的耐药性.
- circ_SIRT1直接与EIF4A3结合,调节ATG12转录并影响自和意马替尼抗性.
结论:
- circ_SIRT1 作为CML中的瘤调节剂.
- circ_SIRT1通过EIF4A3-ATG12通路影响意马替尼抗性.
- circ_SIRT1代表了对伊马替尼布耐药性CML的潜在治疗标.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Electron Transport Chain: Complex I and II
14.2K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.2K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


